Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Theravance Biopharma

05/08/2023 03:02

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
7. 
    * The George Town Grand Cayman-based  company is expected to
report  a 39.6% increase in revenue to $15.421 million from
$11.05 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $14​, above​ its last closing price of $9.95.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.25       -0.25      -0.35     Missed  -42.1
 Dec. 31 2023  -0.17       -0.17      -0.15     Beat    13
 Sep. 30 2022  -0.21       -0.18      -0.21     Missed  -15.1​
 Jun. 30 2022  0.09        0.11       -0.09     Missed  -182.6
 ​​Mar.        -0.11       -0.11      -0.22     Missed  -107.5
 31 2022                                                
 Dec. 31 2021  -0.32       -0.33      -0.43     Missed  -29.7​
 Sep. 30 2021  -0.56       -0.56      -0.48     Beat    14.1
 Jun. 30 2021  -1.02       -1.00      -0.80     Beat    19.9
 This summary was machine generated August 5 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated